RIM
FPRX

RS Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

RS Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$22.3M Sell
539,193
-55,357
-9% -$2.41M 0.23% 166
2016
Q1 		$24.2M Buy
594,550
+83,380
+16% +$2.87M 0.24% 145
2015
Q4 		$21.2M Buy
+511,170
New +$17.1M 0.19% 173

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

RS Investment Management's FPRX Position: Q2 2016 in Review

RS Investment Management reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 9.3% in Q2 2016, selling an estimated $2.41M and leaving 539,193 shares worth $22.3M. The position accounts for 0.23% of the portfolio, ranked #166.

RS Investment Management first reported a position in FPRX in Q4 2015 and has held it in 3 quarters since. The position peaked at $24.2M in Q1 2016. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

  • RS Investment Management held 539,193 shares of Five Prime Therapeutics, Inc. worth $22.3M as of Q2 2016.
  • RS Investment Management sold 55,357 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $2.41M.
  • Five Prime Therapeutics, Inc. made up 0.23% of RS Investment Management's portfolio in Q2 2016, its #166 holding.
  • RS Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and has held it in 3 quarters since.
  • RS Investment Management's Five Prime Therapeutics, Inc. position peaked at $24.2M in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.